Phase 1 N=48 Two Way Bioequivalence Study Under Fed Conditions
Healthy
Primary: Area Under Plasma Concentration — 213.7; 225.9 ng*hr/ml — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children
Influenza
Primary: Number of Subjects With Haemagglutination Inhibition (HI) Antibody Concentrations Above the Cut-off Value — 28; 30 Subjects
Phase 1 N=25 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors
Solid Tumors
Primary: Maximum Tolerated Dose (MTD) of MEDI0639 — NA milligram (mg)
N/A N=1,537 Post Marketing Surveillance Study for Evaluation of Efficacy and Safety of Dotarem in Magnetic Resonance Mammography
MR Mammography With Dotarem
Primary: Image Quality — 495; 898; 118; 8 Participants
N/A N=21 Precision Versus Endurance Training to Improve Walking After Chronic Incomplete SCI
Spinal Cord Injury
Primary: Change in Spinal Cord Injury - Functional Ambulation Profile (SCI-FAP) at Completion of Study — -128.77; -64.07 units on a scale
N/A N=13 Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Metastatic Melanoma
Primary: Occurrence of Dose Limiting Toxicity (DLT) Events — 1; 1 DLT events
N/A N=44,456 Post-marketing Surveillance Study for Evaluation of Dotarem Safety
Contrast-enhanced MRI With Dotarem
Primary: Frequency of Adverse Events — 225 adverse events
Phase 4 N=72 Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder
Bipolar Disorder
Primary: Scores on the California Verbal Learning Test (CVLT-II) at Screening and Week 16 — 50.15; 47.21; 58.88; 52.90 number of total words remembered
Phase 2 N=83 Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares
Gout
Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 84 (Week 12) — 0.79; 0.15 Number of gout flares per participant
Phase 4 N=47 Vortioxetine for Menopausal Depression
Depression · Menopause · Vasomotor Disturbance
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale Score (MADRS) at Week 8 (Visit 5) — -22.8 units on a scale
Phase 1 N=20 Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg
Chronic Hepatitis B
Primary: Change in HBsAg Levels From Baseline to 2 Years — -0.27 log IU/ml — p=<0.05
Phase 3 N=1,038 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
Metastatic Cancer · Prostate Cancer
Primary: Compare Survival Between a Control or Standard Therapy Arm of Docetaxel + Placebo + Prednisone With Docetaxel + Atrasentan + Prednisone in Patients With Hormone…
Phase 2 N=958 Odiparcil For The Prevention Of Venous Thromboembolism
Deep Vein Thrombosis · Fibrillation, Atrial · Venous Thromboembolism
Primary: Percentage of Participants With Total VTE Event Over 10 ± 2 Days of Treatment — 45.1; 44.4; 41.3; 31.2 Percentage of participants — p=0.012
N/A N=60 Saphenous Nerve Block vs. Femoral Nerve Block for Total Knee Arthroplasty
Difference Between Femoral Nerve Block and Saphenous Block
Primary: Visual Analogue Scale Pain Score — 2.81; 2.47 units on a scale
N/A N=229 Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique
Colonoscopy · Digestive System · Endoscopy
Primary: Colonoscopy Success With Minimal Sedation — 57; 32 Participants